Novo's new strategy hinges on something it can't manufacture: investor trust
Novo has now reached the point where it can broaden its ambitions again, CEO Mike Doustdar told CNBC, but investors remain unconvinced.
TL;DR
- Novo Nordisk's shares fell 8% after its Capital Markets Day, failing to convince investors about its strategy to compete after semaglutide loses exclusivity in the early 2030s.
- CEO Mike Doustdar acknowledged the market reaction reflects a need to "do more work on building trust" and that credibility will be rebuilt through financial and scientific results.
- The company announced plans to launch more than five potential blockbuster drugs by 2030, diversifying its pipeline beyond its core diabetes and obesity focus into areas like cardiovascular, liver, and blood disorders.
- Novo Nordisk is betting on a fragmented obesity market with multiple treatments, including drugs focused on moderate weight loss, fewer side effects, greater weight loss, muscle preservation, and pill-based options.
- The company plans to scale manufacturing for weight loss pills to treat 10 times as many people by 2030 and is developing four additional oral obesity assets.